Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria.

ABSTRACT:

Introduction

Post-menopausal women with osteoporosis > 70 years of age at high risk of fracture urgently require treatment for fracture prevention. Moreover, persistence with osteoporosis therapy is critical for real-world effectiveness. We estimated persistence with denosumab in older women at high fracture risk in clinical practice in Bulgaria.

Methods

Eligible participants were post-menopausal women, > 70 years of age, diagnosed with osteoporosis (T-score ≤ - 2.5) and at high risk of fracture (≥ 3% for hip and ≥ 20% for major osteoporotic fracture) who received at least one denosumab injection before enrollment. Planned follow-up was 24 months. The primary endpoint was persistence to denosumab at 12, 18, and 24 months (defined as receiving all denosumab injections within

SUBMITTER: Monov S 

PROVIDER: S-EPMC7990988 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature